Latest News
Investor sentiment was shocked by Trump's 25% tariff on auto imports, increasing inflation fears. But some ETFs performed well, with gains up to 22.8%.
Via Benzinga · March 31, 2025
The Westwood LBRTY Global Equity ETF enables investors to overcome risks linked with economically unstable and corrupt regimes.
Via Benzinga · March 31, 2025
Via The Motley Fool · March 31, 2025
Cryptocurrency markets are trading in a tight sideways range on Monday as markets expect the impact of tariff announcements on Wednesday.
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
ETFs classified as Equity U.S. held 26.83% of the overall assets under management at the end of December 2024.
Via Talk Markets · March 31, 2025
With tariffs coming for more countries in various amounts, a new tool from UPS could help global consumers know the increased prices better.
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
Sabra Healthcare REIT stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 78 to 82 Monday.
Via Investor's Business Daily · March 31, 2025
Goldman Sachs analyst shares key takeaways from 2025 Shoptalk Conference, highlighting conversational and personalized eCommerce, critical video content, and the role of AI in improving brand experience.
Via Benzinga · March 31, 2025
Investors should prepare for a 2008-style crisis.Benzinga warns of potential economic crisis predicted by Peter Schiff in 2008. Tariffs, rising interest rates, misguided Fed policy may cause trouble.
Via Benzinga · March 31, 2025
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.
Via Benzinga · March 31, 2025
In a welcome move, Stryker stock saw its Relative Strength Rating improve to 72 on Monday, up from 69 a day earlier.
Via Investor's Business Daily · March 31, 2025
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
NNOX earnings call for the period ending December 31, 2024.
Via The Motley Fool · March 31, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · March 31, 2025
Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.
Via Benzinga · March 31, 2025
Allspring Global Investments launched two new actively managed ETFs (AGR, ASLV) to provide investors with access to mispriced stocks and value ideas.
Via Benzinga · March 31, 2025
Investors continue to brace for volatility ahead of U.S. President Donald Trump's tariff announcement this week. Fundstrat's Tom Lee believes bullish traders will get rewarded.
Via Benzinga · March 31, 2025
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Via StockStory · March 31, 2025
The Trump family has significantly increased its control over World Liberty Financial, a decentralized finance platform still under development.
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
Via Benzinga · March 31, 2025
Bonds rallied and yields fell not because of inflation and certainly not because of tariffs. It goes back to the growth scare.
Via Talk Markets · March 31, 2025
A Congressman who bought shares of a Bitcoin (CRYPTO: BTC) ETF before President Donald Trump announced an Executi
Via Benzinga · March 31, 2025
Gold prices exceeded $3,000/oz, with potential to reach $3,500 if investment demand rises. China's insurance sector and central banks may increase gold holdings, while ETF inflows signal growing retail interest. Trade policy uncertainty and a weaker U.S. dollar could further support prices.
Via Benzinga · March 31, 2025
Hedge funds are rapidly reducing their investments in global technology stocks, particularly in the semiconductor industry.
Via Talk Markets · March 31, 2025
The energy sector has been running the table year-to-date. Interestingly, the price of crude oil hasn’t participated much in this rally with the energy sector.
Via Talk Markets · March 31, 2025
On March 27, Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google introduced several new features across Search, Maps, and Gemini
Via Benzinga · March 31, 2025
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
Via Benzinga · March 31, 2025
The surge in Arm's data center presence is fueled by the rapid expansion of artificial intelligence, Mohamed Awad, the company’s infrastructure chief, told Reuters.
Via Stocktwits · March 31, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Via Chartmill · March 31, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 31, 2025
FCOJ closed lower and kept the down trends in prices intact. Chart trends are down again on the daily charts.
Via Talk Markets · March 31, 2025
Hut 8 Corp. (NASDAQ: HUT) shares are are trading lower Monday potenafter the company announced it is spinning off its Bitcoin mining operations into a new entity, American Bitcoin, in partnership with Eric Trump.
Via Benzinga · March 31, 2025
AMD announced its fifth-generation EPYC processors power OCI Compute E6 shapes, delivering up to 2x better cost to performance. Stock down 45% in past year.
Via Benzinga · March 31, 2025